A large study shows risperidone raises stroke risk in patients with dementia, even those without cardiovascular disease — ...

A major U.K. study of more than 165,000 dementia patients has found that risperidone raises stroke risk without exception, challenging safety assumptions by leaving no “safe group.” The powerful ...

Amneal has received the Food and Drug Administration’s approval of risperidone extended-release injectable suspension 12.5 mg/vial, 25 mg/vial, 37.5 mg/vial and 50 mg/vial, which is the generic of ...

Teva Pharmaceuticals and Medincell recently announced that the FDA has approved UZEDY® (risperidone), a once-monthly ...

The Food and Drug Administration (FDA) has approved Uzedy ® (risperidone extended-release injectable suspension) as monotherapy or as adjunctive therapy to lithium or valproate for the maintenance ...

Paris: The FDA has approved UZEDY, the first subcutaneous long-acting risperidone formulation utilizing SteadyTeq™ technology, for maintenance treatment of bipolar l disorder-broadening its ...

The FDA expanded the approval of once-monthly risperidone (Uzedy) to include adjunct treatment ... (Wall Street Journal via MSN) The investigational ADHD drug dexmethylphenidate is under FDA review ...

Teva Pharmaceutical Industries Limited (NYSE:TEVA) is one of the best high volume stocks to buy according to Wall Street ...

The once-a-month extended-release injectable suspension incorporates Medincell's copolymer technology. Credit: PhotobyTawat/Shutterstock.com. Teva Pharmaceuticals and ...

A Nigerian pharmacist and researcher, Oyinlade Kehinde, has made a groundbreaking discovery about why the same drugs affect individual patients differently, with a mission to change how doctors ...